PDE4B and gastroparesis: Roflumilast inhibited gastric transit more effectively than selective PDE4B inhibitors, but PDE4 inhibitor-induced gastroparesis wasn’t influenced by gene deletion of any one PDE4 subtype, illustrating that two or more PDE4 subtypes may be involved in this condition.